The role of salvage reirradiation for malignant gliomas that progress on bevacizumab

Journal of Neuro-Oncology

Volumn 97, Issue 3, 2010, Pages 401-407

  Torcuator, Roy G ^a   Thind, Ravneet ^a   Patel, Mehul ^a   Mohan, Y S ^a   Anderson, Joseph ^a   Doyle, Thomas ^a   Ryu, Samuel ^a   Jain, Rajan ^a   Schultz, Lonni ^b   Rosenblum, Mark ^a   Mikkelsen, Tom ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Bevacizumab; Chemotherapy; FSRT; Gliomas; Re irradiation; SRS

Indexed keywords

ANG 1005; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRACTIONATED STEREOTACTIC RADIOTHERAPY; GLIOBLASTOMA; HUMAN; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RETREATMENT; SALVAGE THERAPY; STEREOTACTIC RADIOSURGERY; STEREOTACTIC TREATMENT; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77953292729     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0034-y     Document Type: Article

References (15)

1. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas. Efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787
2. Quant E, Norden A, Drappatz J, Muzikansky A, Doherty L, La- Frankie D, Ciampa A, Kesari K, Wen PY (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11(5):550-555. doi: 10.1215/15228517-2009-006
3. Combs S, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:9963-9969
4. Patel M, Siddiqui F, Jian-Yue J, Mikkelsen T, Rosenblum M, Movsas B, Ryu S (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92:185-191
5. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
6. Jin JY, Yin FF, Ryu S, Ajlouni M, Kim JH (2005) Dosimetric study using different leaf-width MLCs for treatment planning of dynamic conformal arcs and intensity-modulated radiosurgery. Med Phys 32:405-411. doi:10.1118/1.1842911 (Pubitemid 40322321)
7. Jin JY, Ryu S, Faber K, Mikkelsen T, Chen Q, Li S, Movsas B (2006) 2D/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions. Med Phys 33:4557-4566. doi:10.1118/1.2392605 (Pubitemid 44868092)
8. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey L (2008) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156-163
9. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329-336
10. Vredenburgh J, Desjardins A, Herndon J II, Marcello J, Reardon D, Quinn J, Rich J, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner D, Friedman A, Friedman H (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729 (Pubitemid 350086473)
11. Kreisl T, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman J, Camphausen K, Park J, Albert P, Fine H (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745
12. Lai A, Filka E, McGibbon B, Nghiemphu P, Graham C, Yong W, Paul MP, Liau L, Bergsneider M, Pope W, Selch M, Cloughesy T (2008) PHASE II pilot study of bevacizumab in combination temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372-1380
13. Narayana A, Golfinos J, Fisache I, Raza S (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383-389
14. Milas L, Ito H, Hunter N, Jones S, Peters LJ (1986) Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stroma: dependency on tumor type. Cancer Res 46:723-727
15. Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13:193-205